Compare Marathon Petroleum Corp (MPC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Organon & Co. Common Stock — how do they compare? Marathon Petroleum Corp trades at $484.92 (market cap $133.95B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Marathon Petroleum Corp is far larger — about 37× Organon & Co. Common Stock's market cap, and Marathon Petroleum Corp pays the higher dividend (0.84%). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 53 Days and Organon & Co. Common Stock for 0 Days on average.
| MPC | OGN | |
|---|---|---|
Market Cap | $133.95B | $3.62B |
Volume | 1,644,329 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $484.92 | $13.81 |
52-Week Low | $162.63 | $5.70 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $160.47B | $11.04B |
Dividend Yield | 0.84% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $484.92, up 5.69% today, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a reasonable P/E of 16.54. Recent news highlights refining margin strength and positive analyst sentiment, though it faces risks from potential diesel export policy shifts.
The outlook remains positive given tight refining markets and earnings growth projections, but investors should weigh policy risks and high debt levels. Wall Street consensus is strongly bullish with a $444.30 price target, though the current price exceeds this, suggesting near-term caution may be warranted despite long-term fundamentals.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
